Facebook Linkedin Tumblr Twitter
Home Blog Page 13

DELCATH SYSTEMS, INC. (NASDAQ:DCTH) Files An 8-K Unregistered Sales of Equity Securities

By
ME Staff 8-k
-

DELCATH SYSTEMS, INC. (NASDAQ:DCTH) Files An 8-K Unregistered Sales of Equity Securities
Item 3.02 Unregistered Sales of Equity Securities.

As of June 28, 2021, the outstanding shares of common stock, $0.01 par value per share (the “Common Stock”) of Delcath Systems, Inc. (the “Company”) had increased by more than 5% since the last reported shares of Common Stock outstanding.

As of June 28, 2021, the Company had 7,349,777 shares of Common Stock issued and outstanding. The increase in outstanding shares of Common Stock is due to (i) the conversion of 7,651.35 shares of Series E Convertible Preferred Stock into 765,135 shares of Common Stock, (ii) the conversion of 1,122.44 shares of Series E-1 Convertible Preferred Stock into 112,244 shares of Common Stock (iii) the exercise of 3,750 Series F warrants to purchase 3,750 shares of Common Stock, (iv) the exercise of 4,341 Series E and E-1 warrants to purchase 4,341 shares of Common Stock and (v) the exercise of 215,000 pre-funded warrants to purchase 215,000 shares of Common Stock.

About DELCATH SYSTEMS, INC. (NASDAQ:DCTH)

Delcath Systems, Inc. is a late-stage clinical development company with early commercial activity in Europe focused on cancers of the liver. The Company is a specialty pharmaceutical and medical device company developing its product, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS). The Company’s system delivers and filters melphalan hydrochloride, which is marketed as a device under the trade name Delcath Hepatic CHEMOSAT Delivery System for Melphalan (CHEMOSAT). The Company’s focus is on the execution of the clinical development program (CDP) in ocular melanoma liver metastases (mOM), intrahepatic cholangiocarncinoma (ICC), hepatocellular carcinoma (HCC or primary liver) and other cancers that are metastatic to the liver.

Story continues below

DIFFUSION PHARMACEUTICALS INC. (NASDAQ:DFFN) Files An 8-K Submission of Matters to a Vote of Security Holders

By
ME Staff 8-k
-

DIFFUSION PHARMACEUTICALS INC. (NASDAQ:DFFN) Files An 8-K Submission of Matters to a Vote of Security Holders

About DIFFUSION PHARMACEUTICALS INC. (NASDAQ:DFFN)

Diffusion Pharmaceuticals Inc., formerly RestorGenex Corporation, is a clinical-stage biotechnology company. The Company is focused on developing standard-of-care treatments, including radiation therapy and chemotherapy. The Company’s lead product candidate, transcrocetinate sodium, also known as trans sodium crocetinate (TSC) is used in various cancer types, in which tumor oxygen deprivation (hypoxia) is known to diminish the effectiveness of treatments. The Company’s Diffusion’s technology is targeted at overcoming treatment-resistance in solid cancerous tumors by combining its lead product candidate, TSC, with standard-of-care radiation and chemotherapy regimens, thus effecting a better patient survival outcome without the addition of harmful side effects. Its clinical development plan targets TSC at the radiation and chemotherapy sensitization of hypoxic tumor types, with an initial focus on primary brain cancer (glioblastoma or GBM), pancreatic cancer, and brain metastases.

Story continues below

EVOKE PHARMA, INC. (NASDAQ:EVOK) Files An 8-K Other Events

By
ME Staff 8-k
-

EVOKE PHARMA, INC. (NASDAQ:EVOK) Files An 8-K Other Events
Item 8.01.  Other Events.

On June 29, 2021, Evoke Pharma, Inc. (“Evoke” or the “Company”), EVERSANA, the Company’s commercialization partner, and The International Foundation for Gastrointestinal Disorders (“IFFGD”), announced Evoke’s membership into IFFGD Industry Council. Evoke will join a likeminded group of organizations and brands focused on bettering patients affected by gastrointestinal disorders. As part of the Industry Council, Evoke will participate in biannual council meetings to gain industry insights and provide feedback on future plans for IFFGD.

In addition to the Industry Council, Evoke is excited to sponsor the IFFDG’s upcoming 30th Anniversary Digestive Health Virtual Walk in August 2021 during Gastroparesis Awareness Month. This walk is a unique fitness event which will provide participants with an opportunity to engage at their own pace and as their health and schedules permit. To honor the thirty years of the IFFGD’s existence, the overall campaign goal is for all participants to collectively walk 10,950 miles over two weeks. Goals will also go beyond physical fitness by encouraging participants to participate in activities that promote general wellness such as scheduling a doctor’s appointment, trying a new gut friendly recipe or starting a log of their meals and/or symptoms.

Safe Harbor Statement

The Company cautions you that statements included in this report that are not a description of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negatives of these terms or other similar expressions. These statements are based on the Company’s current beliefs and expectations. These forward-looking statements include statements regarding the Company’s plans to increase awareness of gastrointestinal disorders. The inclusion of forward-looking statements should not be regarded as a representation by the Company that any of its plans will be achieved. Actual results may differ from those set forth in this report due to the risks and uncertainties inherent in the Company’s business, including those described in the Company’s periodic filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and the Company undertakes no obligation to revise or update this report to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

About EVOKE PHARMA, INC. (NASDAQ:EVOK)

Evoke Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. EVK-001 is a formulation of Metoclopramide drug, designed to provide systemic delivery of metoclopramide through intranasal administration. The Company has evaluated EVK-001 in a multicenter, randomized, double-blind, placebo-controlled parallel group, dose-ranging Phase IIb clinical trial. The Company has commenced a Phase III clinical trial of EVK-001 in female patients with symptoms associated with acute and recurrent diabetic gastroparesis. The Phase III clinical trial is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study evaluating the efficacy, safety and population pharmacokinetics of EVK-001 in adult females.

Story continues below

USA EQUITIES CORP. (OTCMKTS:USAQ) Files An 8-K Regulation FD Disclosure

By
ME Staff 8-k
-

USA EQUITIES CORP. (OTCMKTS:USAQ) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.

On June 29, 2021, USA Equities Corp. (the “Company”) issued a press release entitled “USA Equities Corp Announces the signing of a Distribution Agreement with a Prominent Physician Management Services Firm For its AllergiEnd® Products and Services.”

A copy of the above-mentioned press release is attached herewith as Exhibit 99.1.

By filing this Current Report on Form 8-K and furnishing the information contained herein, the Company makes no admission as to the materiality of any information in this report that is required to be disclosed solely by reason of Regulation FD. The Company uses, and will continue to use, its website (https://usaqcorp.com), press releases, and various social media channels, including its Twitter account (https://twitter.com/USAQcorp), its LinkedIn account (https://www.linkedin.com/company/usaqcorp) its Facebook account (https://www.facebook.com/USA-Equities-100113722270622), and its Instagram account (https://www.instagram.com/usaqcorp/) as additional means of disclosing public information to investors, the media and others interested in the Company. It is possible that certain information that the Company posts on its website, disseminated in press releases and on social media could be deemed to be material information, and the Company encourages investors, the media and others interested in the Company to review the business and financial information that the Company posts on its website, disseminates in press releases and on the social media channels identified above, as such information could be deemed to be material information.

ITEM 9.01 Financial Statements and Exhibits

99.1 Press release dated June 29, 2021 entitled “USA Equities Corp Announces the signing of a Distribution Agreement with a Prominent Physician Management Services Firm For its AllergiEnd® Products and Services.”


USA EQUITIES CORP. Exhibit
EX-99.1 2 ex99-1.htm   EXHIBIT 99.1     USA Equities Corp Announces the Signing of a Distribution Agreement with a Prominent Physician Management Services Firm For its AllergiEnd® Products and Services   -Continued Momentum Expanding Independent Care Practitioner Network-   West Palm Beach,…
To view the full exhibit click here

About USA EQUITIES CORP. (OTCMKTS:USAQ)

USA Equities Corp., formerly American Biogenetic Sciences, Inc., is a shell company. The Company focuses to seek new business opportunities, including seeking an acquisition or merger with an operating company. The Company’s subsidiary, USA Equities Trust, Inc., is engaged in acquiring real estate. The Company was engaged in the research, development and marketing of cardiovascular and neurobiology products for the purpose of commercial development and vaccines distribution. The Company’s products were designed for in vitro and in vivo diagnostic procedures and therapeutic drugs, and its products had been identified for use in the treatment of epilepsy, migraine and mania, neurodegenerative diseases, coronary artery diseases and cancer. The Company has no operations.

Story continues below

Integrity Applications, Inc. (OTCMKTS:IGAP) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

By
ME Staff 8-k
-

Integrity Applications, Inc. (OTCMKTS:IGAP) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
ITEM 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On June 22, 2021, Luis J. Malavé has been appointed to the Company’s Board of Directors.

Mr. Malavé brings more than 30 years of leadership experience in the MedTech industry, primarily in diabetes management, spanning all company stages, from private startups to large-cap publicly listed companies. He has extensive expertise in product development, operations, marketing, strategic partnerships, and US FDA regulatory strategy.

Since October 2017, Mr. Malavé has served as President of EOFLOW CO. Ltd., a company listed on the Korea Stock Exchange that has developed a wearable disposable insulin pump. From October 2014 to June 2016, he was COO of Mikroscan Technologies. Prior to that, Mr. Malavé was the President and CEO of Palyon Medical, maker of an implantable drug-delivery system that spun out from German medical-technology giant Fresenius SE. Prior to Palyon, he spent nearly a decade at insulin pump maker Insulet Corp., including as its Senior Vice President of Research, Development and Engineering, and as Chief Operating Officer. He also held various senior positions at Medtronic and MiniMed, overseeing product development of various diabetes management devices.

Mr. Malavé earned his Bachelor’s degree in Mathematics and Computer Science from the University of Minnesota, a Master’s degree in Software Engineering from the University of St. Thomas, and an MBA from the University of Maryland.


About Integrity Applications, Inc. (OTCMKTS:IGAP)

Integrity Applications, Inc. is a medical device company. The Company is focused on the design, development and commercialization of non-invasive glucose monitoring devices for use by persons suffering from diabetes. It has developed a non-invasive blood glucose monitor, the GlucoTrack model DF-F glucose monitoring device, which is designed to help people with diabetes obtain blood glucose level readings without the pain, inconvenience, cost and difficulty of conventional (invasive) spot finger stick devices. The Company operates in Europe, and Asia and Pacific. The GlucoTrack model DF-F utilizes a combination of ultrasound, electromagnetic and thermal technologies to obtain blood glucose measurements in less than one minute through a small sensor that is clipped onto one’s earlobe and connected to a small, handheld control and display unit, all without drawing blood.

Story continues below

Corp. (OTCMKTS:CCYPQ) Files An 8-K Termination of a Material Definitive Agreement

By
ME Staff 8-k
-

Corp. (OTCMKTS:CCYPQ) Files An 8-K Termination of a Material Definitive Agreement
Item 1.02 TERMINATION OF A MATERIAL DEFINITIVE AGREEMENT

On June 22, 2021, the Board of Directors of Hammer Fiber Optics Holdings Corp. (“the Company”) held a special meeting of the Board of Directors to discuss the matter of renewal regarding the employment contract of Erik B. Levitt, President and Chief Executive Officer of the Company. The contract is due to expire on September 30th, 2021, with a requirement to provide a notice period of 90 days to Mr. Levitt regarding the Board’s decision to either terminate or extend under the existing terms. The Board unanimously voted not to renew the contract, with Mr. Levitt abstaining from the vote. The context for this decision by the Board of Directors is summarized in Item 8.01 hereunder.

 

Mr. Levitt’s employment as the Company’s Chief Executive under the agreement will terminate on September 30th, 2021. Mr. Levitt will continue in his role as a Director of the Company, as the Principal Financial Officer and as the CEO of the 1stPoint Communications and Endstream Communications subsidiaries, respectively, as further described in Item 8.01.

 

Item 8.01 OTHER EVENTS

Over the past 12 months, the management of Hammer Fiber Optics Holdings Corp. has focused on eliminating debt on the balance sheet of the company since the retraction by Verizon of the licensed spectrum within the 28GHz frequency where the Company designed and deployed innovative broadband technology to cater for its wireless broadband initiative. The cancellation of this license led to defaults on long term service contracts entered into that provided the backbone fiber connectivity to the tower infrastructure of the Company and as such, approximately $4M worth of liabilities were recorded on the balance sheet due to the acceleration of these contracts by the relevant service providers. Following intensive negotiation by the Company’s executive management, these liabilities have been settled in full and the associated liabilities have now been wiped off the balance sheet as recorded in the most recent Form 10-Q filings of the Company.

 

Senior management and the Board of Directors have over the past two years been reevaluating its future wireless broadband strategy and have been making meaningful strides into the rebuilding of its wireless assets and initiatives. The acquisition of the 1stPoint subsidiaries has made this possible and the deployment of wireless broadband services to regions such as Huntsville, Alabama is now well underway. Notwithstanding, the Directors of the Company have actively, over the past two years, researched opportunities that would materially increase shareholder value and as such, have come to the conclusion that the Company would need to implement a diversification strategy into related industry verticals. Since the establishment of the Company’s African broadband initiative which culminated in the incorporation of Hammer Wireless [SL] Ltd, it has become apparent the future success of this initiative would require the full payment for services rendered to broadband customers to be received largely in advance. Consequently, the idea of establishing a method of prepayment of services rendered to local African customers by their family members living abroad [commonly known as remittances] was strongly considered. To cater for this requirement, the Company has explored the idea of developing a FINTECH initiative, consequently providing the group an opportunity to further diversify its strategy.

 

The Company, being desirous of expanding its product offerings across a broader range of related market sectors, has considered entry into the Remittance market serving Africa as it has become extremely opportunistic, representing a market sector of approximately $58 Billion annually in remittance activity. To this end, The Company has entered into negotiation with various financial institutions and FINTECH product developers to create a product offering that would position the Company as a meaningful participant in this extremely lucrative market sector. The diversification strategy into a broader segment of related industry verticals such as cross border bill payment and money remittances and the on-going negotiations between the Board of the Company and that of International FINTECH developers and financial institutions, requires the restructuring of the role of the current management and Board of Directors.

 

Accordingly, the board has explored a strategy whereby the role of the Chief Executive Officer would reside within each active subsidiary or business vertical to make way for the addition of new acquisitions to the Company. Each potential acquisition will require the associated Chief Executive Officer to report to the Board of the Company independently and as such the current Chief Executive role at the parent level will be eliminated. To this end, the employment contract of Mr. Erik B. Levitt, the current Chief Executive Officer, will expire at the end of its three-year term as of September 30th, 2021, to enable the Board to prepare for its diversification strategy. Mr. Levitt will remain an active member of the Board of Directors and will participate in the restructuring initiative of the Company.

 

Story continues below

PHI GROUP, INC. (OTCMKTS:PHIL) Files An 8-K Regulation FD Disclosure

By
ME Staff 8-k
-

PHI GROUP, INC. (OTCMKTS:PHIL) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure

The information in this Item 7.01 of this Current Report is furnished to Item 7.01 and shall not be deemed “filed’ for any purpose, including for the purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that Section. The information in this Current Report on Form 8-K shall not be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act regardless of any general incorporation language in such filing.

I. Extension of Repurchase Date for the Company’s Common Stock

On June 25, 2021, the Board of Directors of PHI Group, Inc., a corporation originally incorporated in the State of Nevada on June 08, 1982 and redomiciled in the State of Wyoming on September 20, 2017 (the “Company”), adopted the following resolutions in lieu of a meeting:

WHEREAS, on December 28, 2020 the Company’s Board of Directors passed a corporate resolution to extend the time period for the repurchase of its own shares of common stock from the open market from time to time in accordance with the terms mentioned below:


PHI GROUP INC Exhibit
SEC.gov | Request Rate Threshold Exceeded html {height: 100%} body {height: 100%; margin:0; padding:0;} #header {background-color:#003968; color:#fff; padding:15px 20px 10px 20px;font-family:Arial,…
To view the full exhibit click here

About PHI GROUP, INC. (OTCMKTS:PHIL)

PHI Group, Inc. is engaged in mergers and acquisitions. The Company focuses on acquiring operating businesses in selective industries and invests in various ventures that may create long-term value for its shareholders. In addition, the Company also provides corporate finance services, including merger and acquisition advisory and consulting services for client companies through its subsidiary, PHI Capital Holdings, Inc. The Company’s business involves acquisitions of energy assets, as well as production and trading of energy commodities. The Company will continue to pursue its merger and acquisition program by acquiring all or controlling interests in target companies in various industries, including but not limited to conventional energy, renewables, natural resources, agribusiness, technology, transportation, education, distribution, mining, oil and gas, financial Services, healthcare and pharmaceuticals.

Story continues below

IEH Corporation (OTCMKTS:IEHC) Files An 8-K Regulation FD Disclosure

By
ME Staff 8-k
-

IEH Corporation (OTCMKTS:IEHC) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.

On June 24, 2021 IEH Corporation issued a press release, a copy of which appears and is attached hereto as Exhibit 99.1.

The information provided in Item 7.01 of this Current Report on Form 8-K and in the attached exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. This Current Report will not be deemed an admission as to the materiality of any information in this report that is being disclosed to Regulation FD.

Item 9- Financial Statements and Exhibits

Exhibit 99.1          Press Release dated June 24, 2021.


IEH Corp Exhibit
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1   Press Release of IEH Corporation,…
To view the full exhibit click here

About IEH Corporation (OTCMKTS:IEHC)

IEH Corporation designs, develops and manufactures printed circuit connectors for high performance applications. The Company offers circular product line of connectors for the medical industry, which also includes connector cable assemblies. The Company also offers a plastic circular connector line. Its products line features high-density connectors. All of the Company’s connectors utilize its HYPERBOLOID contact design, a contact system for high-stress environments. It produces HYPERBOLOID in the United States. The Company is primarily a manufacturer and its products are basic components of assemblies of finished goods. It sells products directly and through approximately 20 independent sales representatives located in all regions of the United States, Canada, Israel, India, various Pacific Rim countries, South Korea and the European Union (EU). It offers various products under the Military Qualified Product Listing (QPL).

Story continues below

LAKE SHORE BANCORP, inc. (NASDAQ:LSBK) Files An 8-K Other Events

By
ME Staff 8-k
-

LAKE SHORE BANCORP, inc. (NASDAQ:LSBK) Files An 8-K Other Events
Item 8.01Other Events.



The Company’s Board of Directors reported that as of June 23, 2021 it had completed the repurchase of shares from the stock repurchase plan put in place during August 2020.  The Company repurchased 111,949 shares under the plan at an average cost of $14.42 per share since the plan’s inception in August 2020.



















































About LAKE SHORE BANCORP, inc. (NASDAQ:LSBK)

Lake Shore Bancorp, Inc. is a savings and loan holding company of Lake Shore Savings Bank (the Bank). The Bank’s loan portfolio consists of real estate loans and other loans. The real estate loans consist of residential one- to four-family, home equity, commercial and construction loans. The Bank’s other loans consists of commercial and consumer loans. The Bank provides all-in-one home equity lines of credit to its customers. The Bank’s primary sources of funds consist of deposits, scheduled amortization and prepayments of loans and securities, maturities and sales of investments and loans, interest earning deposits at other financial institutions and funds provided from operations. The Company operates through over 10 branch offices. It has branches in Chautauqua County, New York, which are located in Dunkirk, Fredonia, Jamestown, Lakewood and Westfield. In Erie County, New York, its branch offices are located in Depew, East Amherst, Hamburg, Kenmore, Orchard Park and Snyder.

Story continues below

SINO-GLOBAL SHIPPING AMERICA, LTD. (NASDAQ:SINO) Files An 8-K Other Events

By
ME Staff 8-k
-

SINO-GLOBAL SHIPPING AMERICA, LTD. (NASDAQ:SINO) Files An 8-K Other Events
Item 8.01

 


Sino-Global Shipping America, Ltd. Exhibit
EX-99.1 2 ea143363ex99-1_sinoglobal.htm PRESS RELEASE OF SINO-GLOBAL SHIPPING AMERICA,…
To view the full exhibit click here

About SINO-GLOBAL SHIPPING AMERICA, LTD. (NASDAQ:SINO)

Sino-Global Shipping America, Ltd. is a non-asset-based global shipping and freight logistic integrated solution provider. The Company provides solutions and value added services to its customers in the shipping and freight logistic chain sector. The Company’s segments include Shipping Agency and Ship Management Services; Shipping & Chartering Services, and Inland Transportation Management Services. The Company conducts its business primarily through its subsidiaries in China (including Hong Kong), Australia, Canada, and the United States (New York and Los Angeles). The Company provides its shipping agency services in the People’s Republic of China through Sino-Global Shipping Agency Ltd. (Sino-China), which holds the licenses and permits to operate local shipping agency services in the People’s Republic of China. The Company’s inland transportation management services are operated by its subsidiaries in China (including Hong Kong) and the United States.

Story continues below
1...121314...14,628Page 13 of 14,628

EDITOR PICKS

POPULAR POSTS

POPULAR CATEGORY

© Market Exclusive 2019